# NATALEE (NCT03701334)

> A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03701334
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Early Breast Cancer
- Interventions: Ribociclib; Endocrine Therapy (ET)
- Enrollment: 5101
- Primary outcome: Invasive Disease-Free Survival (iDFS)

## Commentary we found

- X threads: 329
- YouTube: 100
- Podcasts: 69
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=natalee-nct03701334

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03701334", "email": "<work email>"}; the inbox owner confirms by the emailed link.